aspirin has been researched along with Dementia Praecox in 23 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two previous randomized controlled trials (RCTs) suggested that adjunctive aspirin is efficacious in treating schizophrenia." | 9.41 | Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. ( Boronin, L; Davidson, M; Davis, JM; Gonen, I; Levi, L; Matei, V; Nacu, A; Nastas, I; Radu, P; Weiser, M; Zamora, D, 2021) |
| "Aspirin given as adjuvant therapy to regular antipsychotic treatment reduces the symptoms of schizophrenia spectrum disorders." | 9.14 | Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. ( Burger, H; Grobbee, DE; Heijnen, CJ; Kahn, RS; Laan, W; Selten, JP, 2010) |
| "To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia." | 9.01 | Acetylsalicylic acid (aspirin) for schizophrenia. ( Friedel, J; Phelps, E; Schmidt, L; Shokraneh, F, 2019) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 7.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Two previous randomized controlled trials (RCTs) suggested that adjunctive aspirin is efficacious in treating schizophrenia." | 5.41 | Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. ( Boronin, L; Davidson, M; Davis, JM; Gonen, I; Levi, L; Matei, V; Nacu, A; Nastas, I; Radu, P; Weiser, M; Zamora, D, 2021) |
| "Aspirin given as adjuvant therapy to regular antipsychotic treatment reduces the symptoms of schizophrenia spectrum disorders." | 5.14 | Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. ( Burger, H; Grobbee, DE; Heijnen, CJ; Kahn, RS; Laan, W; Selten, JP, 2010) |
| "To review the effects of acetylsalicylic acid (aspirin) as adjunct (add-on) or as stand-alone treatment for people with schizophrenia." | 5.01 | Acetylsalicylic acid (aspirin) for schizophrenia. ( Friedel, J; Phelps, E; Schmidt, L; Shokraneh, F, 2019) |
| "Antipsychotic drugs plus aspirin (acetylsalicylic acid), which targets prostaglandin-endoperoxide synthase 1 (PTGS1: COX1), improved therapeutic outcomes when treating schizophrenia." | 3.88 | Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin. ( Dean, B; Gibbons, A; Gogos, A; Scarr, E; Thomas, E; Udawela, M, 2018) |
| "Neuropsychiatric disorders place a very high burden on the global health and economy." | 2.61 | Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive agents in the treatment of psychiatric disorders. ( Altinoz, MA; Ozpinar, A, 2019) |
| "In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness." | 2.49 | Putative neuroprotective agents in neuropsychiatric disorders. ( Anderson, G; Berk, M; Dean, OM; Dodd, S; Maes, M; Moylan, S, 2013) |
| "The pharmacologic treatment of schizophrenia and bipolar disorder leaves much to be desired." | 2.48 | Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. ( Davis, JM; Torrey, EF, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (47.83) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, L | 1 |
| Phelps, E | 1 |
| Friedel, J | 1 |
| Shokraneh, F | 1 |
| Altinoz, MA | 1 |
| Ozpinar, A | 1 |
| Weiser, M | 1 |
| Zamora, D | 1 |
| Levi, L | 1 |
| Nastas, I | 1 |
| Gonen, I | 1 |
| Radu, P | 1 |
| Matei, V | 1 |
| Nacu, A | 1 |
| Boronin, L | 1 |
| Davidson, M | 1 |
| Davis, JM | 2 |
| Dean, B | 1 |
| Gibbons, A | 1 |
| Gogos, A | 1 |
| Udawela, M | 1 |
| Thomas, E | 1 |
| Scarr, E | 1 |
| Webb, JR | 1 |
| Webb, JE | 1 |
| Stubbe, DE | 1 |
| Poncin, YB | 1 |
| Laan, W | 1 |
| Grobbee, DE | 1 |
| Selten, JP | 1 |
| Heijnen, CJ | 1 |
| Kahn, RS | 1 |
| Burger, H | 1 |
| Torrey, EF | 1 |
| Shader, RI | 1 |
| Dodd, S | 1 |
| Maes, M | 1 |
| Anderson, G | 1 |
| Dean, OM | 1 |
| Moylan, S | 1 |
| Berk, M | 1 |
| Luchins, D | 1 |
| Fangio, P | 1 |
| De Jonghe, B | 1 |
| Lachérade, JC | 1 |
| Terville, JP | 1 |
| Outin, H | 1 |
| Flye, MW | 1 |
| Mundinger, GH | 1 |
| Schulz, SC | 1 |
| Karsh, J | 1 |
| Van Kammen, DP | 1 |
| Nedopil, N | 1 |
| Dieterle, D | 1 |
| Matussek, N | 1 |
| Hippius, H | 1 |
| Gurland, HJ | 1 |
| Hillebrand, G | 1 |
| Das, I | 1 |
| Khan, NS | 1 |
| Turner, P | 1 |
| Boullin, DJ | 1 |
| Orr, MW | 1 |
| Solomon, GF | 1 |
| Moos, RH | 1 |
| Fessel, WJ | 1 |
| Morgan, EE | 1 |
| Greenbaum, DM | 1 |
| Togba, J | 1 |
| Blecker, J | 1 |
| Grace, WJ | 1 |
| Baker, M | 1 |
| Rundle, F | 1 |
| Barnes, AJ | 1 |
| Gutteridge, JM | 1 |
| Stocks, J | 1 |
| Dormandy, TL | 1 |
| Friedman, D | 1 |
| Moskowitz, MD | 1 |
| Rosen, M | 1 |
| Rossman, M | 1 |
| Sheppard, C | 1 |
| Merlis, S | 1 |
| Drtil, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder[NCT01320982] | Phase 3 | 400 participants (Anticipated) | Interventional | 2011-03-31 | Not yet recruiting | ||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Aspirin as Adjuvant Therapy in Young Psychotic Patients[NCT02685748] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2017-07-20 | Completed | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
4 reviews available for aspirin and Dementia Praecox
| Article | Year |
|---|---|
Acetylsalicylic acid (aspirin) for schizophrenia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvant; Huma | 2019 |
Acetylsalicylic acid and its metabolite gentisic acid may act as adjunctive agents in the treatment of psychiatric disorders.
Topics: Anti-Inflammatory Agents; Antioxidants; Aspirin; Bipolar Disorder; Gentisates; Humans; Inflammation; | 2019 |
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; An | 2012 |
Putative neuroprotective agents in neuropsychiatric disorders.
Topics: Animals; Aspirin; Bipolar Disorder; Depressive Disorder; Humans; Lithium; Mental Disorders; Nerve Gr | 2013 |
4 trials available for aspirin and Dementia Praecox
| Article | Year |
|---|---|
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials.
Topics: Adult; Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Schizophrenia; Tre | 2021 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Chemotherapy, Adjuvan | 2010 |
Psychopathology in systemic lupus erythematosus. I. Psychiatric observations.
Topics: Adolescent; Adult; Affective Symptoms; Aspirin; Azathioprine; Brain Diseases; Clinical Trials as Top | 1973 |
Effects of chlormezanone on anxiety and tension: a double blind study.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Aspirin; Bipolar Disorder; Chlormezanone; Clini | 1966 |
15 other studies available for aspirin and Dementia Praecox
| Article | Year |
|---|---|
Studies on Prostaglandin-Endoperoxide Synthase 1: Lower Levels in Schizophrenia and After Treatment with Antipsychotic Drugs in Conjunction with Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aspirin; Bipolar Disorder; B | 2018 |
Aspirin as an adjunctive treatment for childhood onset schizophrenia.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Aripiprazol | 2013 |
Too good to be true? Aspirin and schizophrenia.
Topics: Aspirin; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Reproducibility of Resu | 2012 |
Typical versus atypical antipsychotics.
Topics: Antipsychotic Agents; Aspirin; Drug Costs; Humans; Myocardial Infarction; Prevalence; Schizophrenia; | 2004 |
Coronary spasm in a 59-yr-old woman with hyperventilation.
Topics: Alkalosis, Respiratory; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antihypertensive Ag | 2004 |
Successful creation of arteriovenous fistulas in nonuremic patients with heparin and aspirin therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arm; Arteriovenous Shunt, Surgical; Arthritis, Rheum | 1981 |
[Blood purification of chronic schizophrenic patients. Results of an "open" study (author's transl)].
Topics: Adult; Aspirin; Female; Hemoperfusion; Humans; Male; Schizophrenia | 1980 |
Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects.
Topics: Adult; Antipsychotic Agents; Arachidonic Acid; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; | 1998 |
Schizophrenia as a prostaglandin deficiency disease.
Topics: Aspirin; Depression, Chemical; Humans; Indomethacin; Prostaglandins; Schizophrenia | 1977 |
Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine.
Topics: Aged; Aspirin; Chlorpromazine; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Platelet Agg | 1976 |
Globulins and behavior in schizophrenia.
Topics: Aspirin; Chlorambucil; gamma-Globulins; Humans; Immunoglobulin M; Male; Middle Aged; Phenothiazines; | 1966 |
Salicylate intoxication: an unusual presentation.
Topics: Adult; Ampicillin; Aspirin; Bicarbonates; Bronchi; Bronchoscopy; Carbon Dioxide; Diuresis; Fluphenaz | 1974 |
The dilemma of a prison doctor.
Topics: Anesthesia; Arthritis; Aspirin; Behavior Therapy; Delivery of Health Care; Fluphenazine; Hostility; | 1972 |
Haemolytic syndrome associated with a red cell lipid abnormality.
Topics: Adult; Aldehydes; Anemia, Hemolytic; Arachidonic Acids; Aspirin; Chromatography, Gas; Codeine; Eryth | 1973 |
Analgesics-antipyretics and etiology and pathogenesis of psychosis.
Topics: Adult; Aggression; Aminopyrine; Analgesics; Aspirin; Female; Hallucinations; Humans; Male; Paranoid | 1971 |